Novel Drug Cuts Proteinuria in APOL1-Mediated Kidney Disease

(MedPage Today) -- An investigative treatment targeting APOL1 activity significantly improved proteinuria APOL1-mediated kidney disease (AMKD), a proof-of-concept phase IIa study found. In a single-arm, open-label study, treatment with oral VX...
Source: MedPage Today Nephrology - Category: Urology & Nephrology Source Type: news